- Home
- NRXS vs MNOV Comparison
NRXS vs MNOV Comparison
Compare NRXS & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | MNOV |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.9M | 68.4M |
| IPO Year | 2023 | 2004 |
Fundamental Metrics
Financial Performance| Metric | NRXS | MNOV |
|---|---|---|
| Price | $5.97 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $7.50 |
| AVG Volume (30 Days) | ★ 89.0K | 37.6K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,569,282.00 | $2,360,807.00 |
| Revenue This Year | $172.91 | N/A |
| Revenue Next Year | $115.71 | $180.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 32.89 | ★ 194.15 |
| 52 Week Low | $2.21 | $1.17 |
| 52 Week High | $9.33 | $1.96 |
Technical Indicators
Market Signals| Indicator | NRXS | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 39.42 | 54.22 |
| Support Level | $5.59 | $1.27 |
| Resistance Level | $7.54 | $1.44 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 43.67 | 42.84 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.